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Abstract
Introduction: Studies have shown that a two-gene ratio (HOXB13:IL17BR) and a five-gene (BUB1B, CENPA, NEK2,
RACGAP1, RRM2) molecular grade index (MGI) are predictive of clinical outcomes among early-stage breast cancer
patients. In an independent population of lymph node-negative breast cancer patients from a community hospital
setting, we evaluated the performance of two risk classifiers that have been derived from these gene signatures
combined, MGI+HOXB13:IL17BR and the Breast Cancer Index (BCI).
Methods: A case-control study was conducted among 4,964 Kaiser Permanente patients diagnosed with node-
negative invasive breast cancer from 1985 to 1994 who did not receive adjuvant chemotherapy. For 191 cases
(breast cancer deaths) and 417 matched controls, archived tumor tissues were available and analyzed for
expression levels of the seven genes of interest and four normalization genes by RT-PCR. Logistic regression
methods were used to estimate the relative risk (RR) and 10-year absolute risk of breast cancer death associated
with prespecified risk categories for MGI+HOXB13:IL17BR and BCI.
Results: Both MGI+HOXB13:IL17BR and BCI classified over half of all ER-positive patients as low risk. The 10-year
absolute risks of breast cancer death for ER-positive, tamoxifen-treated patients classified in the low-, intermediate-,
and high-risk groups were 3.7% (95% confidence interval (CI) 1.9% to 5.4%), 5.9% (95% CI 3.0% to 8.6%), and 12.9%
(95% CI 7.9% to 17.6%) by MGI+HOXB13:IL17BR and 3.5% (95% CI 1.9% to 5.1%), 7.0% (95% CI 3.8% to 10.1%), and
12.9% (95% CI 7.1% to 18.3%) by BCI. Those for ER-positive, tamoxifen-untreated patients were 5.7% (95% CI 4.0%
to 7.4%), 13.8% (95% CI 8.4% to 18.9%), and 15.2% (95% CI 9.4% to 20.5%) by MGI+HOXB13:IL17BR and 5.1% (95% CI
3.6% to 6.6%), 18.6% (95% CI 10.8% to 25.7%), and 17.5% (95% CI 11.1% to 23.5%) by BCI. After adjusting for tumor
size and grade, the RRs of breast cancer death comparing high- versus low-risk categories of both classifiers
remained elevated but were attenuated for tamoxifen-treated and tamoxifen-untreated patients.
Conclusion: Among ER-positive, lymph node-negative patients not treated with adjuvant chemotherapy, MGI
+HOXB13:IL17BR and BCI were associated with risk of breast cancer death. Both risk classifiers appeared to provide
risk information beyond standard prognostic factors.
Introduction
Previously, it was shown that a simple homeobox B13:
interleukin 17 receptor B two-gene ratio (hereafter referred
to as HOXB13:IL17BR) could predict recurrence in a sam-
ple of patients with estrogen receptor (ER)-positive breast
cancer receiving adjuvant tamoxifen therapy [1]. Subse-
quent results suggest that HOXB13:IL17BR may be both
prognostic (that is, predictive of disease outcome) and pre-
dictive of tamoxifen benefit (that is, tamoxifen response/
resistance) [2-4].
More recently, a five-gene (budding uninhibited by ben-
zimidazoles 1 homolog beta (BUB1B), centromere protein
A (CENPA), never in mitosis gene a-related kinase 2
(NEK2), Rac GTPase-activating protein 1 (RACGAP1),
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ribonucleotide reductase M2 (RRM2)) tumor grade signa-
ture (MGI for molecular grade index) was developed to
recapitulate tumor grade. In one study, MGI predicted
clinical outcome of early-stage breast cancer patients with
comparable performance to much more complex gene
signatures [5]. Furthermore, MGI and HOXB13:IL17BR
have been used together (hereafter referred to as MGI
+HOXB13:IL17BR) to stratify ER-positive lymph node-
negative patients treated with endocrine therapy into three
risk groups (low, intermediate, and high) [5]. Both signa-
tures have also been newly combined to derive a patient
risk score (range: 0 to 10), reflective of the rate of distant
metastasis at 10 years post-diagnosis, known as the Breast
Cancer Index (BCI) [6].
The purpose of this study was to evaluate the perfor-
mance of MGI+HOXB13:IL17BR and BCI, as defined pre-
viously [5,6], in an independent study population of
ER-positive, lymph node-negative breast cancer patients
who were not treated with chemotherapy. A prespecified
primary aim was to assess the degree to which the MGI+-
HOXB13:IL17BR risk classifier predicts the risk of breast
cancer-specific mortality among tamoxifen-treated
ER-positive, node-negative patients, either alone or after
accounting for tumor size and tumor grade. A prespecified
secondary aim was to similarly examine the extent to
which the MGI+HOXB13:IL17BR predicts the risk of
breast cancer-specific mortality among tamoxifen-
untreated ER-positive, node-negative patients. With
the recent development of the BCI, the study aims were
expanded to include a parallel evaluation of this newer
risk classifier.
Materials and methods
Study population and design
We conducted a case-control study nested within a
cohort of 4,964 potentially eligible breast cancer patients.
This same patient population was used in a previously
described study of Oncotype DX (Genomic Health, Inc.,
Redwood City, CA, USA) [7]. The study was approved by
the Kaiser Permanente Northern California Institutional
Review Board (IRB). Informed consent from study parti-
cipants was waived by the IRB.
Briefly, the Northern California Kaiser Permanente
tumor registry was used to identify all female health plan
members aged less than 75 years who were diagnosed
with lymph node-negative invasive breast cancer from
1985 to 1994. Breast cancer patients were eligible if their
initial disease was not treated with chemotherapy. Patients
were excluded for the following reasons: inflammatory or
bilateral breast cancer or evidence of metastasis (including
lymph nodes) at initial diagnosis; prior invasive cancer
(breast or other) at diagnosis; or unknown/unconfirmed
treatment with tamoxifen.
Patients were followed until death due to breast cancer,
death from another cause, bilateral breast cancer, termina-
tion of membership, or December 2002, whichever came
first. Cases were patients whose first event was death from
breast cancer. For each case, up to three controls were
randomly selected from patients alive and under follow-up
at the time of the case’s death (that is, risk set sampling)
[8]. Cases and controls were matched on age (within one
year), race (non-Hispanic white, Hispanic, Black, Asian),
calendar year of diagnosis (exact year), Kaiser Permanente
pathology department of origin, and treatment of index
breast cancer with tamoxifen (yes, no). Initial diagnosis,
treatment, and cause of death were confirmed through
medical chart review.
Of the 402 cases identified as potentially eligible by the
tumor registry, 269 were determined to be eligible by
chart review. Of the 989 controls initially matched to the
identified cases, 722 were determined to be eligible by
chart review. Of those eligible by chart review, 31 cases
and 91 controls were excluded because of missing tumor
blocks. Four additional cases who could not be matched
to at least one control were excluded, leaving 234 cases
and 631 controls available for pathology-based studies.
Blinding and batching of pathology and laboratory
procedures
All pathology and laboratory procedures, including slide
review, sectioning of tumor blocks, macrodissection, RT-
PCR assays, and gene expression analyses, were conducted
blinded to the case-control status of patient specimens. In
addition, both cases and controls were included in every
batch of pathology materials sent to bioTheranostics (San
Diego, CA, USA) for gene expression analyses.
Sample preparation
Breast cancer samples (three to six 10 micron unstained
tissue sections plus one H&E-stained slide per sample)
were provided to bioTheranostics for gene expression ana-
lysis. The H&E slides were reviewed by a pathologist at
bioTheranostics to identify prominent tumor areas. Sam-
ples containing no tumor or primarily noninvasive lesions
were excluded from further analysis. Of the 220 cases and
570 controls included in our previous study on Oncotype
DX, there were 13 cases or controls with insufficient
tumor for this study; an additional two controls became
uninformative because their matched case had no tumor
tissue. For the remaining samples, macrodissection by
scalpel was performed on adjacent unstained sections to
enrich for tumor cells. Macrodissected tissue sections
were treated with 2 mg/ml Proteinase K (Invitrogen,
Carlsbad, CA, USA) overnight at 50°C. Total RNA was
extracted using the RNA Cleanup kit (Zymo Research,
Orange, CA, USA) and treated with RNase-free DNase
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(Epicentre, Madison, WI, USA), and absence of genomic
DNA contamination was confirmed for all samples.
Adequate RNA was obtained for 191 cases and 417 con-
trols. The distribution of factors available from the tumor
registry (diagnosis year, age, race, tumor size, ER status
and tamoxifen treatment) was fairly similar in the 269
chart-eligible cases compared to the 191 RT-PCR-evalu-
able cases. This also was true for chart-eligible and evalu-
able controls. However, lost cases and controls were
slightly more likely to be younger or to have smaller
tumors. Furthermore, the distribution of characteristics,
including tumor size and grade, in this study population
presented in Table 1 is quite similar to the distribution
among the slightly larger group of patients in our. Onco-
type DX study.
Gene selection for HOXB13:IL17BR and MGI
HOXB13 and IL17BR were previously identified from a
microarray analysis of 60 patients with hormone receptor-
positive breast cancer treated with the standard five years
of adjuvant tamoxifen therapy [1]. A simple HOXB13:
IL17BR two-gene ratio was proposed as a novel biomarker
of prognosis and response to tamoxifen.
From a microarray analysis of 36 breast cancer speci-
mens, a set of 39 genes was identified with increased
expression in high-grade tumors [5]. The high correlation
with tumor grade was confirmed in a large publicly avail-
able microarray data set (Uppsala cohort). The list of 39
genes was then narrowed to five, based on functional
annotation of the genes, association with clinical outcome
in the Uppsala cohort, and correlation with tumor grade
in an independent sample of 60 patients as described
previously [5].
Gene expression analysis by RT-PCR
Expression of 11 genes of interest (ER, progesterone recep-
tor (PR), human epidermal growth factor receptor
2 (HER2), HOXB13, IL17BR, choline dehydrogenase
(CHDH), BUB1B, CENPA, NEK2, RACGAP1, RRM2) and
four normalization genes (beta-actin (ACTB), hydro-
methylbilane synthase (HMBS), succinate dehydrogenase
complex, subunit A (SDHA) and ubiquitin C (UBC)) were
measured by TaqMan RT-PCR. RNA samples were con-
verted to cDNA by reverse transcription with Super-
Script™ III (Invitrogen). Each cDNA sample was analyzed
in duplicate on a 384-well plate for each gene using real-
time TaqMan™ assay on an ABI 7900HT instrument
Table 1 Selected characteristics of the study population:










White, non-Hispanic 146(76%) 326(78%)



















ER status from RT-PCR2
Positive 145(76%) 370(89%)
Negative 46(24%) 47(11%)
PR status from RT-PCR2
Positive 117(61%) 324(78%)
Negative 74(39%) 93(22%)
Table 1 Selected characteristics of the study population:
191 cases, 417 controls. (Continued)




Low risk 71(37%) 222(53%)
High risk 120(63%) 195(47%)
MGI
Low risk 51(27%) 197(47%)
High risk 140(73%) 220(53%)
MGI+HOXB13:IL17BR
Low risk 51(27%) 197(47%)
Intermediate risk 50(26%) 108(26%)
High risk 90(47%) 112(27%)
BCI
Low risk 55(29%) 222(53%)
Intermediate risk 54(28%) 85(20%)
High risk 82(43%) 110(26%)
1Modified Bloom-Richardson grading criteria; 2performed by Genomic Health,
Inc. (ER cut points ≤ 6.5 and >6.5 units; PR cut points <5.5 and ≥5.5 units;
HER2 cut points <11.5 and ≥11.5 units).
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(Applied Biosystems, Foster City, CA, USA). All primers
and probes have been described before [2]. We used the
average threshold cycle (Ct) value (ref_mean) of the four
reference genes as a measure of RNA input in the RT-
PCR assay. A prespecified acceptance criterion used in this
study was ref_mean <29.
Calculation of gene expression indices
All methods for processing the raw RT-PCR data and cal-
culating HOXB13:IL17BR and MGI were identical to prior
studies [2,5,6]. HOXB13:IL17BR was dichotomized at the
value of 0.06 (< = 0.06 vs. >0.06) and MGI was dichoto-
mized at the value of 0 (< = 0 vs. >0) into low- and high-
risk groups. Both indices were also combined following
two previously described approaches [5,6]. One approach
uses HOXB13:IL17BR and MGI in their dichotomous
form to stratify patients into three groups: low risk (low
MGI), intermediate risk (high MGI but low HOXB13:
IL17BR), and high risk (high MGI and high HOXB13:
IL17BR). The other employs both indices in their contin-
uous form to derive a continuous risk score (that is, BCI).
The BCI is computed as a polynomial function of





= 0.4431 ∗ mgi + 0.4972 ∗ hi − 0.09 ∗ hi3,















It has been also used to stratify patients into three risk
groups: low (BCI <5), intermediate (5 ≤ BCI <6.4), and
high (BCI ≥ 6.4).
Quality control assessment
The potential impact of within-person heterogeneity and
batch heterogeneity was examined. Each batch of samples
to bioTheranostics included two blinded internal con-
trols. These controls came from seven different patients,
each of which was in multiple (four to eight) batches of
samples (total of 17 batches). Of 34 internal controls
sent, only 23 had sufficient RNA from five patients,
which were included in 16 of the 17 batches. With
respect to risk classification by MGI, all replicate controls
were concordant for each patient. With respect to risk
classification by HOX13:IL17BR and MGI+HOX13:
IL17BR, all replicates for four patients and two of three
replicates for one patient were concordant. With respect
to risk classification by BCI, all replicates for two patients
were concordant. For the remaining three patients, four
of eight, two of three, and three of five replicates were
concordant.
Tumor size, grade and ER status
Tumor size was ascertained from pathology review of all
H&E slides collected from all surgeries at diagnosis, when
not documented in the pathology report (7% of reports).
Tumor grade was assessed by two board-certified assistant
professors in pathology using the modified Bloom-
Richardson grading criteria [9], based on their indepen-
dent reviews of an H&E slide from the most representative
tumor block.
For a sizable proportion (16%) of patients, ER status of
the index tumor was not indicated in the 10- to 20-year-
old medical records. All tumors were therefore classified
as ER-positive or ER-negative according to ER expression
determined through RT-PCR by Genomic Health, Inc.
(ER-positive >6.5), an approach consistent with our prior
research [7]. ER status was also determined through RT-
PCR by bioTheranostics (ER-positive >-2.5) [2] and
through immunohistochemistry (IHC) by PhenoPath
Laboratories (Seattle, WA, USA) (ER positivity >1% anti-
gen staining). Agreement for ER status classification
between Genomic Health RT-PCR and IHC was better (
= 0.85; 95% CI: 0.78 to 0.91) [10] than that between
Genomic Health and bioTheranostics RT-PCR methods
( = 0.62; 95% CI: 0.55 to 0.70).
Statistical analysis
Statistical analyses were conducted entirely by Kaiser
Permanente researchers according to a prespecified
plan, with results generated for patient groups based on
ER status and tamoxifen treatment.
Conditional logistic regression was used to calculate
odds ratios as estimates of the relative risks (RR) of breast
cancer death associated with each risk classifier, unad-
justed (univariate analyses) and adjusted for tumor size
and tumor grade (multivariable analyses). Tumor size was
examined both continuously in 2 cm units (for consistency
with results from our prior study [7]) and categorically
(≤1.0 cm, 1.1 to 2.0 cm, 2.1 to 4.0 cm, and >4.0 cm).
Tumor grade was examined as a categorical variable (well
differentiated, moderately differentiated, and poorly differ-
entiated) using data from the standardized rereview. We
examined tumor grade separately for pathologist 1 and
pathologist 2 but present data for pathologist 1 only (for
consistency with results from our prior study [7]). We also
created tumor group categories that combined tumor size
and grade largely using consensus group recommenda-
tions on adjuvant treatment [11,12]. The three categories
were as follows: Tumor Group 1 (≤ 2.0 cm and well or ≤
1.0 cm and moderate); Tumor Group 2 (>2.0 cm and well,
or 1.1 to 2.0 cm and moderate, or ≤ 2.0 cm and poor);
Tumor Group 3 (>2.0 cm and moderate/poor). Model
parameters were estimated by maximum likelihood, and
95% confidence limits were calculated by the Wald
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method. Statistical significance was evaluated using the
likelihood ratio test [13].
We performed separate analyses for women with ER-
positive tumors who received or did not receive tamoxi-
fen. Because ER status was not a matching factor but was
associated with breast cancer death, only 14 of the 46
ER-negative cases were matched to ER-negative controls.
Therefore, for women with ER-negative tumors who did
not receive tamoxifen, we derived RR estimates from
conditional logistic regression analyses of all untreated
patients using terms for interaction with ER status. In
addition, we derived RR estimates for each prespecified
patient group from conditional logistic regression ana-
lyses of all patients using interaction terms for ER status
and tamoxifen therapy. Since these results were not
materially different, we present only results from analyses
conducted within patient groups. Also, since the limited
number of ER-negative patients yielded very imprecise
estimates, we present results for ER-positive patients
only.
As described previously (see Appendix in Habel et al.
[7]), methods developed by Langholz and Borgan [14] for
nested case-control data were adapted to our control
sampling scheme and applied to estimate the absolute
risk of breast cancer death at 10 years and corresponding
95% confidence intervals. Estimates were ascertained for
prespecified categories of MGI+HOXB13:IL17BR, BCI,
tumor size, and tumor grade for subgroups of ER-positive
patients stratified on tamoxifen treatment. Ten-year risks
of breast cancer death were also calculated for both treat-
ment subgroups of ER-positive patients when cross-clas-
sified by tumor size and grade; by MGI+HOXB13:
IL17BR, tumor size, and grade; and by BCI, tumor size,
and grade.
Results
Characteristics of cases and controls
Breast cancer deaths occurred a median of 4.7 years after
diagnosis. Among the cases and controls, the median
tumor size was 1.5 cm (range 0.2 to 7.0 cm). Cases and
controls were comparable with respect to matching factors
including age, race, diagnosis year, and tamoxifen treat-
ment (Table 1). Overall, about one-third of patients
received adjuvant tamoxifen treatment. Prior to 1989, 10%
of patients were treated with tamoxifen, whereas from
1989 to 1994, 61% of patients were treated with tamoxifen.
Among those treated with tamoxifen, the median duration
was four years; 10% had a year of treatment or less. Com-
pared to controls, cases more commonly had tumors that
were ER negative, PR negative, larger, or more poorly
differentiated.
Cases were also more likely than controls to have
tumors with higher MGI+HOXB13:IL17BR or higher
BCI values. However, 71 (37%) of the 191 cases were
discordant by the two risk classifiers. We found that 90
(47%) of 191 total cases were classified as high risk by
MGI+HOXB13:IL17BR and 82 (43%) were classified as
high risk by BCI. We also found that 111 (27%) of 417
controls were discordant by the two risk classifiers.
Among the controls, we found that 197 (47%) were clas-
sified as low risk by MGI+HOXB13:IL17BR; 222 (53%)
were classified as low risk by BCI.
For prespecified analyses stratified by ER status and
tamoxifen therapy, there were 49 cases and 112 matched
controls who were tamoxifen-treated and had ER-posi-
tive tumors by the RT-PCR assay. There were 90 cases
and 174 matched controls who had ER-positive tumors
by the RT-PCR assay and were not treated with tamoxi-
fen. There were 12 cases and 15 matched controls who
had ER-negative tumors by the RT-PCR assay and were
not treated with tamoxifen. In addition, a small number
of ER-negative patients were treated with tamoxifen
(two cases and two matched controls).
Distribution of risk classifier categories by tumor
characteristics
All four risk classifiers were correlated with tumor size
and, as expected for MGI, even more strongly with tumor
grade, along with ER, PR, and HER2 status (Table 2).
Women with breast tumors that were larger in size, more
poorly differentiated, ER negative, PR negative, and HER2
positive were more likely to be classified as high risk. A
number of patients with these same tumor characteristics,
however, were classified as low risk.
Relative risks for breast cancer death: ER-positive patients
In ER-positive patients treated with tamoxifen, the risk
for breast cancer death was positively associated with
HOXB13:IL17BR, MGI, MGI+HOXB13:IL17BR, and BCI
in models without tumor size and tumor grade (Table 3).
The relative risks (RR) remained elevated for the higher
categories of each risk classifier when tumor size and
grade were added to the models, although only the RR
for high risk defined by the BCI remained statistically
significant.
Similarly, in ER-positive patients not treated with
tamoxifen, the risk for breast cancer death was positively
associated with each of the four risk classifiers (Table 3).
However, none of the RRs for the high-risk categories
remained statistically significant after tumor size and
grade were added to the models. Associations were gen-
erally weaker in magnitude among ER-positive patients
without (versus with) tamoxifen therapy.
Increased risk for breast cancer-specific mortality was
associated with higher tumor grade in tamoxifen-treated
ER-positive patients and with both higher tumor grade
and larger tumor size in tamoxifen-untreated ER-positive
patients (data not shown). These associations remained
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Table 2 Distributions of tumor characteristics for categories of HOXB13:IL17BR, MGI, and MGI+HOXB13:IL17BR, and BCI.
























≤ 1.0 97 (58%) 71 (42%) 91 (54%) 77 (46%) 91 (54%) 39 (23%) 38 (23%) 96 (57%) 37 (22%) 35 (21%) 168
1.1 - 2.0 130 (48%) 141 (52%) 105 (39%) 166 (61%) 105 (39%) 77 (28%) 89 (33%) 119 (44%) 62 (23%) 90 (33%) 271
>2.0 66 (39%) 103 (61%) 52 (31%) 117 (69%) 52 (31%) 42 (25%) 75 (44%) 62 (37%) 40 (24%) 67 (40%) 169
Tumor grade1
Well 95 (66%) 49 (34%) 103 (72%) 41 (28%) 103 (72%) 24 (17%) 17 (12%) 106 (74%) 29 (20%) 9 (6%) 144
Moderate 133 (51%) 128 (49%) 134 (51%) 127 (49%) 134 (51%) 73 (28%) 54 (21%) 144 (55%) 68 (26%) 49 (19%) 261
Poor 65 (32%) 138 (68%) 11 (5%) 192 (95%) 11 (5%) 61 (30%) 131 (65%) 27 (13%) 42 (21%) 134 (66%) 203
Tumor size and grade2
Group 1 129 (66%) 66 (34%) 129 (66%) 66 (34%) 129 (66%) 42 (22%) 24 (12%) 134 (69%) 45 (23%) 16 (8%) 195
Group 2 106 (40%) 156 (60%) 80 (31%) 182 (69%) 80 (31%) 76 (29%) 106 (40%) 93 (36%) 60 (23%) 109 (42%) 262
Group 3 58 (38%) 93 (62%) 39 (26%) 112 (74%) 39 (26%) 40 (26%) 72 (48%) 50 (33%) 34 (23%) 67 (44%) 151
ER status
Positive 274 (53%) 241 (47%) 237 (46%) 278 (54%) 237 (46%) 140 (27%) 138 (27%) 259 (50%) 119 (23%) 137 (27%) 515
Negative 19 (20%) 74 (80%) 11 (12%) 82 (88%) 11 (12%) 18 (19%) 64 (69%) 18 (19%) 20 (22%) 55 (59%) 93
PR status
Positive 257 (58%) 184 (42%) 211 (48%) 230 (52%) 211 (48%) 126 (29%) 104 (24%) 239 (54%) 99 (22%) 103 (23%) 441
Negative 36 (22%) 131 (78%) 37 (22%) 130 (78%) 37 (22%) 23 (19%) 98 (59%) 38 (23%) 40 (24%) 89 (53%) 167
HER2 status
Positive 12 (16%) 62 (84%) 16 (22%) 58 (78%) 16 (22%) 11 (15%) 47 (64%) 23 (31%) 16 (22%) 35 (47%) 74
Negative 281 (53%) 253 (47%) 232 (43%) 302 (57%) 232 (43%) 147 (28%) 155 (29%) 254 (48%) 123 (23%) 157 (29%) 534














evident, although not necessarily statistically significant,
after adding MGI, MGI+HOXB13:IL17BR or BCI to the
models.
When estimating RRs for breast cancer-specific mor-
tality for different time periods after initial breast cancer
diagnosis, results suggested that risk classifiers were bet-
ter predictors of short (<5 years) vs. long-term (≥5
years) mortality (data not shown). In other sensitivity
analyses, RRs generated for ER-positive patients changed
little when further adjusting for HER2 status.
Absolute risk of breast cancer death at 10 years: ER-
positive patients
Figure 1 presents the absolute risk of breast cancer death
at 10 years post-diagnosis associated with each risk classi-
fier for tamoxifen-treated and tamoxifen-untreated ER-
positive patients. The 10-year absolute risks of breast
cancer death for ER-positive, tamoxifen-treated patients
were 3.7% (95% CI 1.9% to 5.4%), 5.9% (95% CI 3.0% to
8.6%), and 12.9% (95% CI 7.9% to 17.6%) for those in the
low-, intermediate- and high-risk groups, respectively,
when classified by MGI+HOXB13:IL17BR. Risks were
similar in magnitude when classified by BCI, with corre-
sponding estimates of 3.5% (95% CI 1.9% to 5.1%), 7.0%
(95% CI 3.8% to 10.1%), and 12.9% (95% CI 7.1% to
18.3%). In comparison, those for ER-positive patients not
treated with tamoxifen were generally higher, being 5.7%
(95% CI 4.0% to 7.4%), 13.8% (95% CI 8.4% to 18.9%), and
15.2% (95% CI 9.4% to 20.5%) when classified by MGI
+HOXB13:IL17BR and 5.1% (95% CI 3.6% to 6.6%), 18.6%
(95% CI 10.8% to 25.7%), and 17.5% (95% CI 11.1% to
23.5%) when classified by BCI.
When classifying ER-positive patients by tumor size
and grade alone into three groups (of increasing tumor
Table 3 Relative risks (RR) of breast cancer death associated with each risk classifier among ER-positive patients,
stratified by treatment with tamoxifen.
Cases Controls
Risk classifier n % n % RR1 95% CI RR2 95% CI
Tamoxifen treated (49 cases and 112 controls)
HOXB13:IL17BR
Low risk 19 39% 58 52% 1.0 ref 1.0 ref
High risk 30 61% 54 48% 1.9 0.9 - 3.7 1.5 0.7 - 3.2
MGI
Low risk 12 24% 55 49% 1.0 ref 1.0 ref
High risk 37 76% 57 51% 2.9 1.3 - 6.2 2.1 0.8 - 5.5
MGI+HOXB13:IL17BR
Low risk 12 24% 55 49% 1.0 ref 1.0 ref
Intermediate risk 14 29% 31 28% 1.8 0.7 - 4.8 1.3 0.4 - 4.2
High risk 23 47% 26 23% 3.5 1.5 - 8.1 2.7 0.9 - 7.5
BCI
Low risk 13 27% 61 54% 1.0 ref 1.0 ref
Intermediate risk 15 31% 29 26% 2.2 0.9 - 5.6 2.1 0.8 - 6.0
High risk 21 43% 22 20% 4.2 1.7 - 10.3 3.3 1.1 - 10.3
Tamoxifen untreated (90 cases and 174 controls)
HOXB13:IL17BR
Low risk 41 46% 101 58% 1.0 ref 1.0 ref
High risk 49 54% 73 42% 1.6 1.0 - 2.7 1.3 0.8 - 2.3
MGI
Low risk 32 36% 99 57% 1.0 ref 1.0 ref
High risk 58 64% 75 43% 2.6 1.5 - 4.8 1.7 0.8 - 3.4
MGI+HOXB13:IL17BR
Low risk 32 36% 99 57% 1.0 ref 1.0 ref
Intermediate risk 27 30% 39 22% 2.5 1.3 - 4.8 1.7 0.8 - 3.6
High risk 31 34% 36 21% 2.9 1.4 - 5.8 1.6 0.7 - 3.8
BCI
Low risk 30 33% 108 62% 1.0 ref 1.0 ref
Intermediate risk 26 29% 28 16% 3.9 1.9 - 8.0 3.2 1.5 - 6.8
High risk 34 38% 38 22% 3.6 1.8 - 7.4 2.0 0.8 - 4.9
1Univariate conditional logistic regression models include HOXB13:IL17BR, MGI, MGI+HOXB13:IL17BR or BCI; 2multivariable conditional logistic regression models
include HOXB13:IL17BR, MGI, MGI+HOXB13:IL17BR or BCI plus tumor size (≤2.0,>2.0) and grade (well, intermediate, poor).
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size and grade), the absolute 10-year risks of breast cancer
death were 3.0% (95% CI 1.3% to 4.7%), 7.1% (95% CI 4.7%
to 9.5%), and 12.2% (95% CI 6.3% to 17.8%) among those
treated and 5.1% (95% CI 3.3% to 6.9%), 10.5% (95% CI
7.7% to 13.3%), and 15.9% (95% CI 9.6% to 21.7%) among
those untreated. Although fairly comparable in magnitude
to the MGI+HOXB13:IL17BR-classified and BCI-classified
risk groups (presented above), these estimates varied when
further cross-classified by MGI+HOX13:IL17BR or BCI.
Of those who died within five years of initial diagnosis,
29%, 30% and 41% were classified by MGI+HOXB13:
IL17BR and 37%, 24%, and 39% were classified by BCI as
low, intermediate and high risk, respectively. Of those who
died between five and ten years, 44%, 29% and 27% were
classified by MGI+HOXB13:IL17BR and 52%, 23%, and
25% were classified by BCI as low, intermediate and high
risk, respectively. Of those who died 10 or more years after
diagnosis, 53%, 26% and 21% were classified by MGI
+HOXB13:IL17BR and 58%, 10%, and 32% were classified
by BCI as low, intermediate and high risk, respectively.
Discussion
In a large, independent population of patients with lymph
node-negative invasive breast cancer not treated with che-
motherapy, we were able to validate reported associations
of MGI+HOX13:IL17BR and BCI with breast cancer death
among ER-positive patients treated with tamoxifen. We
also noted associations, although less pronounced for
increasing risk categories of MGI+HOX13:IL17BR and
BCI, among ER-positive patients not treated with tamoxi-
fen. Both risk classifiers appeared to provide risk informa-
tion beyond tumor size and tumor grade and classified
over 50% of ER-positive patients as low risk for breast can-
cer death.
Several methodological limitations should be consid-
ered when interpreting our findings. Since we lacked ER
status from the medical records for a substantial propor-
tion of patients, we defined ER status based on gene
expression. However, the risk estimates were not materi-
ally changed when analyses were restricted to the 84% of
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Figure 1 Estimated 10-year absolute risks of breast cancer death associated with each risk classifier, tumor size, and tumor grade
among ER-positive patients, stratified by treatment with tamoxifen. Each diamond symbol denotes the absolute risk of breast cancer death
at 10 years (y-axis). The horizontal line through each diamond symbol denotes the corresponding 95% CI. The vertical lines mark a 10-year
absolute risk of 10%, the conventional cut point used in deciding whether or not breast cancer patients should receive adjuvant chemotherapy.
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records (data not shown). Due to the diagnosis years of
the study (1985 to 1994), only 30% of patients received
tamoxifen treatment. While this proportion is consistent
with what has been reported for other patient popula-
tions during this period [15], the number of tamoxifen-
treated patients was limited for analysis. Given that the
cases and controls were matched with respect to tamoxi-
fen treatment, we could not directly examine whether
MGI+HOXB13:IL17BR and BCI are able to identify
patients who are likely to respond to tamoxifen therapy.
We did find a slightly stronger association between each
risk classifier and risk for breast cancer death among
tamoxifen-treated than tamoxifen-untreated patients,
suggesting that both risk classifiers capture response to
tamoxifen therapy as well as prognosis. This observation
is consistent with evidence that HOXB13:IL17BR is asso-
ciated with response to tamoxifen [3].
In recent years, a number of gene expression signatures
have been developed in an attempt to classify the likely
prognosis and/or response to therapy for patients with
invasive breast cancer better than can currently be done
with standard histopathologic features, such as tumor
size, tumor grade, ER and HER2 status [16]. Each of
these gene expression signatures requires validation in
multiple independent populations of patients before its
clinical utility can be firmly established. Although only
one, MammaPrint, has been FDA approved, there are at
least three others that are commercially available, includ-
ing Oncotype DX, MapQuant Dx, and BCI. MammaPrint
and Oncotype DX are currently being examined in pro-
spective clinical trials of breast cancer treatment in both
adjuvant and neoadjuvant settings. Many of the others
are undergoing validation in retrospective samples from
clinical trial populations, in defined cohorts of patients
treated in referral centers or the community setting, or in
convenience samples of patients from a variety of
sources. Both MammaPrint and Oncotype DX are multi-
marker signatures (70 and 21 genes, respectively) that
include genes from several important carcinogenic path-
ways (for example, proliferation and hormone response).
BCI and MapQuant Dx include a set of genes to specifi-
cally provide a genomic signature for tumor grade. There
are only a small number of genes, however, that appear
in more than one of the many signatures.
In our validation study, the performance of MGI
+HOXB13:IL17BR and BCI were evaluated using the
same risk categories defined in previous studies, specifi-
cally among well-characterized subgroups of ER-positive
breast cancer patients who did and did not receive
tamoxifen. For each patient, pathology reports and diag-
nostic slides were systematically reviewed to confirm
breast cancer diagnosis and uniformly assess tumor size
and grade. Course of treatment and vital status were also
confirmed by medical record review. In addition, gene
expression arrays were conducted blinded to the case-
control status of all specimens.
Our results are fairly similar to the three studies that
have previously evaluated MGI+HOXB13:IL17BR and/or
BCI [5,6,17]. We found that the combination of MGI and
HOXB13:IL17BR signatures was a stronger prognostic
indicator than each signature alone among ER-positive
breast cancer patients treated with tamoxifen, as demon-
strated previously [5], and among those untreated. As in
the study by Jerevall et al. [6], the RR of breast cancer
death was associated with both signatures combined irre-
spective of whether tamoxifen was received, although the
associations that we observed were more pronounced
among treated than untreated patients. Analyses limited to
post-menopausal breast cancer patients with tumors of ≤
3.0 cm, the subgroup equivalent to the Jerevall et al. study
population, yielded associations weaker in magnitude
(data not shown). However, our estimated 10-year risks of
breast cancer death for tamoxifen-treated and untreated
patients classified by MGI+HOXB13:IL17BR as low risk
(that is, 3.7% and 5.7%) were commensurate to theirs (that
is, 2.3% and 5.3%). Risk classification using their BCI algo-
rithm likewise produced comparable results. For tamoxi-
fen-treated and untreated ER-positive patients classified as
low risk by the BCI, absolute risks of breast cancer death
at 10 years post-diagnosis were 1.1% and 5.1% in their
study and 3.5% and 5.1% in ours. In the only other study
to evaluate the BCI to date [17], corresponding estimates
for low-risk patients receiving adjuvant tamoxifen with or
without chemotherapy or adjuvant tamoxifen alone were
3.8% and 7.2%, respectively.
Although both risk classifiers combining MGI and
HOXB13:IL17BR scores appear to offer added prognostic
information, our data suggest that it is still important to
consider standard clinicopathologic variables in risk
assessment. For example, in analyses that cross-classified
ER-positive breast cancer patients by either risk classifier,
tumor size, and tumor grade, the 10-year absolute risk of
breast cancer death was relatively low for tamoxifen-trea-
ted patients presenting with small, low-grade tumors in all
three MGI+HOXB13:IL17BR or BCI risk groups. This
finding, although intuitive, should be interpreted cau-
tiously until confirmed by others, given the limited num-
ber of patients studied. It should be further noted that
MGI+HOXB13:IL17BR and BCI were developed examin-
ing ER-positive, lymph node-negative patients treated with
tamoxifen. Therefore, the utility of both risk classifiers in
determining breast cancer prognosis are not necessarily
generalizable to other populations, including patients trea-
ted with aromatase inhibitors.
Conclusions
In an independent population of lymph node-negative
invasive breast cancer patients who did not receive
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adjuvant chemotherapy, we demonstrate that MGI
+HOXB13:IL17BR and BCI are associated with risk of
breast cancer death among ER-positive patients treated
and untreated with tamoxifen. Both risk classifiers
appeared to capture risk of breast cancer death beyond
traditional clinicopathologic indicators and identified a
sizable fraction of patients at low risk of mortality.
Additional research is needed to determine whether
these risk classifiers are also predictors of tamoxifen
response and whether their clinical utility for prognosti-
cation extends to other subpopulations of breast cancer
patients.
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